. Randomization was stratified for primary refractoriness against induction therapy and length of first remission in relapsed patients. From 186 evaluable patients, 88 (47%) and 10 cases (5%) achieved a complete (CR) or partial (PR) remission, 39 patients (21%) had persisting leukemia (non-response (NR)), and 49 cases (26%) died within 6 weeks after the start of therapy (early death (ED)). In patients younger than 60 years the higher dose level resulted in a significant reduction of NR (12% vs 31%; ordinal 2 test: P = 0.01) but also a higher rate of ED (32% vs 17%) thus leading to a marginally higher CR rate only (52% vs 45%). Within the subgroup of patients with refractory AML the tendency towards a higher CR rate after HD-AraC was more pronounced (46% vs 26%; P = 0.045). In patients older than 60 years, corresponding though less evident differences were observed with a higher rate of NR in the lower dose group (26% vs 16%) and ED occurring more frequently after higher doses (36% vs 26%). These data indicate that HD-AraC reveals a significantly higher antileukemic efficacy than ID-AraC as expressed by a significant reduction of failure from NR. This advantage, however, does not fully translate into an increase in remission rate due to a higher incidence of ED after HD-AraC predominantly from uncontrolled infections. In order to take full advantage of the higher antileukemic activity of HD-AraC an improvement of supportive care and infection control is warranted.
Introduction
Cytosine arabinoside (AraC) is one of the oldest drugs in leukemia therapy and is still the most active single agent in the treatment of adults with AML. It hence provides the basis for most currently used regimens. 1 After having demonstrated that high doses of AraC reveal a substantial activity in refractory and relapsed AML, increased doses of AraC have also been incorporated into first-line therapy. In prospective randomized studies a long-term beneficial effect could in fact be demonstrated by the application of HD-AraC during induction 2, 3 or consolidation. 4 In spite of these achievements, the most appropriate dose of higher than conventional doses, ie higher than 100 to 200 mg/m 2 per single application, is still not clearly defined. Pharmacokinetic investigations indicated that the intracellular enzyme doxycytidine kinase -catalysing the formation of AraC triphosphate, which is considered as the main cytotoxic component -is saturated at concentrations that are achieved by short-term infusions of 0.5 to 1.0 g/m 2 . 5, 6 These observations indicate that further dose escalation may not increase the antileukemic activity but only the drug-associated toxicity to normal organs. Recent findings, however, suggest that the cytotoxic activity of AraC may be mediated by additional mechanisms other than from the incorporation of AraC triphosphate into the DNA strand. Cytotoxicity may also result from interferences of AraC with the metabolism of membrane lipids 7, 8 or from the alteration of intracellular signalling 9, 10 and apoptosis. [11] [12] [13] These effects may be dosedependent and could be further enhanced by increasing drug dosage. The current study addressed the question of a dosedependent activity of AraC on the basis of a prospective randomized comparison of HD-AraC vs ID-AraC in patients with refractory and relapsed AML on the basis of the sequential high-dose AraC and mitoxantrone (S-HAM) regimen.
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Patients and methods
Patients
Consecutive patients at ages 18 years or older with relapsed and refractory AML who were admitted to the participating centers between September 1987 and September 1992 were eligible for the study. The diagnosis of AML was based on the revised French-American-British (FAB) Group criteria. 15 Refractoriness against standard chemotherapy was defined according to previously established criteria. 16 These included: (1) primary resistance against two cycles of induction therapy; (2) first early relapse with a remission duration of less than 6 months; (3) second and subsequent relapse. Patients with first relapses after 6 months remission duration were not considered refractory to standard therapy and were included as relapsed AML.
All patients were recruited from the first-line trials of the German AML Cooperative Group and had thus received a standardized first-line treatment. In patients less than 60 years of age first-line therapy consisted of double induction therapy with either the repetitive application of the 9-day regimen of thioguanine, AraC, daunorubicin (TAD-9/TAD-9) or the sequential application of TAD-9 followed by HD-AraC and mitoxantrone (HAM). Older patients all received one course of TAD-9 and were treated by a second TAD-9 course only upon inadequate response to the first TAD-9 cycle. Patients of all ages who achieved a complete remission subsequently received TAD-9 for consolidation and monthly maintenance therapy for 3 years. 17, 18 Patients with antecedent hematologic disorders, secondary leukemias, and a preceding autologous or allogeneic bone marrow transplantation were excluded from the study. Further exclusion criteria comprised coronary heart disease, heart failure, cardiomyopathy, severe arterial hypertension, abnormal liver function tests (aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase (AP) more than three times the upper normal limits, total bilirubin Ͼ2.0 mg/dl), impaired renal function (serum creatinine Ͼ2.0 mg/dl), severe infections or pregnancy.
Antileukemic therapy
Patients meeting the entry criteria were enrolled into the current study and were treated by S-HAM 14 comprising AraC every 12 h by a 3-h infusion on days 1, 2, 8 and 9 and mitoxantrone 10 mg/m 2 /day as a 30-min infusion on days 3, 4, 10 and 11, respectively ( Figure 1 ). Patients younger than 60 years were randomly assigned to receive AraC at doses of either 3.0 g/m 2 or 1.0 g/m 2 per application while older patients were randomized to either 1.0 g/m 2 or 0.5 g/m 2 AraC per single dose. To avoid imbalances in the patients' risk profile randomization was stratified for the following criteria:
(1) primary resistance against two cycles of induction therapy; (2) first early relapse with a remission duration of less than 6 months; (3) first relapse with a remission duration of more than 6 months but less than 18 months; (4) first relapse with a remission duration of more than 18 months; (5) second and subsequent relapse.
No hematopoietic growth factors were applied at any time. To prevent HD-AraC-induced photophobia and conjunctivitis all patients received glucocorticoid eye drops every 6 h starting before the first dose and continuing for 24 h after the last dose of HD-AraC. Antimicrobial prophylaxis consisted of cotrimoxazol 960 mg p.o. three times daily, colistine sulphate
Figure 1
Schedule of the sequential high-dose AraC and Mitoxantrone protocol (S-HAM).
two million units p.o. four times daily, and amphotericin B suspension 40 mg p.o. six times daily.
Study parameters
Bone marrow examinations were carried out on day 18, ie 1 week after the end of chemotherapy and upon full recovery of peripheral blood counts. Response to therapy was assessed according to CALGB criteria. 19 CR was defined as a normal cellular bone marrow with normal erythroid and myeloid elements and less than 5% myeloblasts, and with peripheral blood counts of more than 100 000/l platelets and more than 1500/l granulocytes for at least 4 weeks. Patients with regenerated peripheral blood values but more than 5% and less than 25% myeloblasts were considered to be in PR, as were patients fulfilling the bone marrow criteria of CR but without full recovery of peripheral blood platelet and/or white blood cell counts. Patients with persisting leukemic blasts in the bone marrow or blood or with leukemic regrowth within 4 weeks after initial response were considered as nonresponders. Patients dying within 6 weeks after the start of antileukemic therapy without evidence of leukemic regrowth were classified as ED.
The duration of critical cytopenia was evaluated by the time of granulocyte recovery to more than 500/l and platelet recovery to more than 20 000/l from the onset of S-HAM treatment. The time to CR was measured from the onset of treatment to the date of documented CR and disease-free survival from the date of documented CR to relapse or death during remission. Survival and time to treatment failure were measured by the time from the beginning of treatment to death, documentation of persisting leukemia, or relapse, respectively.
Toxicity was evaluated according to the World Health Organization (WHO) grading system. 20 
Statistics
The primary end point of the present study was the impact of HD-AraC on the CR rate and the disease-free survival as compared to a randomly assigned control group receiving IDAraC. Assuming an improvement of 20% in the CR rate by HD-AraC with ␣ = 0.05 and ␤ = 0.20, 76 patients were anticipated to be enrolled into each treatment arm. Secondary end points were the rates of NR and ED as well as the incidence of hematologic and non-hematologic side-effects. Numerical values were compared by the Fisher's exact test. Response to antileukemic therapy was compared by an ordinal 2 test. Remission duration and survival was calculated according to Kaplan-Meier estimates. Comparisons were carried out using the log-rank test.
Study conduct
Prior to therapy all patients gave their informed consent for participation in the current evaluation after having been advised about the purpose and investigational nature of the study, as well as of potential risks. The study design adhered to the declaration of Helsinki and was approved by the ethics committees of the participating institutions prior to its initiation.
Results
Patient characteristics
Two hundred and twelve patients were entered into the study from 28 centers in Germany and Austria, 186 of whom were fully evaluable. Causes for exclusion from analysis were death before start of therapy (one); secondary leukemia (three); treatment not in accordance with the result of randomization (four); incomplete documentation (nine); and early discontinuation of therapy on day 5 (nine). The latter patients were evenly distributed between the four groups AraC. The patients' ages ranged from 18 to 75 years (median 50 years) and did not differ between the respective groups (Table 1 ). All patients had received prior chemotherapy for their disease as indicated above. Twenty-one patients younger than 60 years had been treated with the HAM regimen as part of the induction therapy in each group. Overall, 27 (15%) patients had primary refractory disease and 43 (23%) had early relapses after a first CR of less than 6 months duration. In 71 (38%) and 30 (16%) cases the relapses occurred after a CR of more than six but less than 18 months and of more than 18 months duration, respectively; 15 (8%) patients suffered from second or subsequent relapses ( Table 1 ). The comparison of the profile of disease status revealed a similarity for all four study groups. AML subtypes were predominantly M1, M2, M4 and M5. All 186 patients received one course of S-HAM therapy only.
Antileukemic activity
Overall, 88 (47%) and 10 (5%) of the 186 evaluable patients achieved a CR and PR, respectively, while 39 (21%) cases were non-responders. Forty-nine (26%) patients suffered from ED (Table 2 ). Within the group of patients younger than 60 years the application of HD-AraC appeared to be superior to ID-AraC (ordinal 2 test: P = 0.01) with more patients achieving a CR (52% vs 45%) and a reduction of failure from NR (12% vs 31%). In the high-dose group, however, more early deaths occurred (32% vs 17%) which in most cases were due to severe infections (27% vs 11%; P = 0.01). The beneficial effect of HD-AraC was more pronounced in the subgroup of patients with refractory disease or early relapse (ordinal 2 test: P = 0.045; Table 3 ) with CR rates of 46% vs 26% and failure from NR of 19% vs 61%. No differences were observed for time to treatment failure (median 2.9 vs 2.4 months, P = 0.88), disease-free survival (median 5.3 vs 3.3 months, P = 0.35; Figure 2) , or overall survival (median 4.2 vs 5.3 months, P = 0.78).
In patients older than 60 years the CR rate was similar after both dose levels. As in the younger patient groups, the more intensive therapy resulted in fewer cases with NR and more early deaths (Table 2 ). However, due to the lower number of evaluable patients these differences were not statistically significant.
Side-effects
The dose-intensity of AraC had no influence on the recovery time of granulocytes to more than 500/l, which amounted to a median of 41 vs 39 days in patients younger than 60 years and of 38 vs 35 days in older patients (Figure 3) . Also, in patients achieving a CR the time to CR did not differ between the respective groups (54 vs 61 days in younger patients, P = 0.31; 48 vs 46 days in older cases, P = 0.74).
The non-hematologic side-effects that were encountered during S-HAM therapy are summarized in Tables 4 and 5 . Overall, the most frequent side-effects were infections, nausea/vomiting, diarrhoea, stomatitis and bleeding. In patients younger than 60 years infections (78% vs 63%; P = 0.04) and stomatitis (47% vs 28%; P = 0.02) were significantly more often recorded in the high-dose group but there were no differences in both severe infections (59% vs 49%) and severe stomatitis (12% vs 9%) according to WHO grade III/IV. Severe nausea/vomiting and diarrhoea (WHO grade III/IV) occurred slightly more frequently in the high-dose group. Only patients having received 3 g/m 2 AraC had severe disturbances of consciousness (10% vs 0%; P = 0.01). The incidences of bleeding as well as of the remaining side-effects were similar for both groups (Table 4 ). In older patients there 
Figure 3
Recovery from critical cytopenia; patients Ͻ60 years: 41 vs 39 days (P = 0.92); patients Ͼ60 years: 38 vs 35 days (P = 0.31).
Table 4
Non-hematologic side-effects in patients younger than 60 years 19 (26) 11 (17) Diarrhoea (%)
15 (21) 8 (12) Stomatitis (%) 9 (12) 6 (9) Bleeding (%) 7 (10)
2 (3) 1 (2) a P = 0.01.
Table 5
Non-hematologic side-effects in patients older than 60 years 
were no significant differences in the side-effects with the profile being similar to that observed in younger patients (Table 5) .
Discussion
With the increasing use of AraC at higher than conventional doses, the determination of the most appropriate and effective dose is clinically warranted and yet unanswered. This is particularly relevant for the antileukemic activity of AraC whereas a dose response relation has already been established for nonhematologic toxicities. The current study addressed the question of HD-AraC vs ID-AraC as a prospective randomized comparison of 3.0 g/m 2 vs 1.0 g/m 2 dose of AraC in patients . The results obtained at the two different dose levels in patients younger than 60 years reveal a superior antileukemic efficacy of HD-AraC as compared to ID-AraC (ordinal 2 test: P = 0.01) with more patients achieving a complete remission (52% vs 45%) and particularly a significant reduction in NR (12% vs 31%). This favorable effect was counterbalanced, however, by a higher rate of ED, most of which were due to severe infections (27% vs 11%; P = 0.01). Since the duration of severe neutropenia was not prolonged, HD-AraC obviously must have impaired the defense mechanisms against infections in a different way or may have influenced the type of infections, respectively. In preceding studies, an increased rate of bacterial infections by Streptococcus viridans 21 and a higher frequency of pneumonia 22 have been reported, both of which are associated with a high mortality. Among several other factors the dosedependent damage of mucosal membranes may at least in part explain the increased susceptibility to these complications. 23 In line with these findings, a higher frequency of stomatitis was observed in patients being assigned to the high-dose arm of the current trial. The differences also found in CNS toxicity were not unexpected. 24, 25 The analysis of patient subgroups indicated that particularly cases with primary NR to induction therapy and short duration of first remissions appear to benefit from HD-AraC. Within this high-risk group of patients 16 a higher CR rate was achieved (42% vs 33%) and persisting leukemia occurred significantly less frequent (16% vs 47%). However, as observed for the whole study group, there were also more early deaths (35% vs 13%). In the other subgroups, ID-AraC seemed equally effective and less toxic as compared with HD-AraC.
While there are numerous studies comparing high-dose with conventional-dose AraC in the treatment of patients with AML, the current study is the first one to assess the antileukemic efficacy and side-effects of HD-AraC vs ID-AraC. A variety of uncontrolled phase II studies has been performed with both doses mostly in combination with anthracyclines. The overall results particularly in the high-risk group of patients with refractory and relapsed disease are comparable with the present study (Table 6 ). In these trials, CR rates ranged from 34 to 58% vs 23 to 66% for HD-AraC vs ID-AraC and failure from NR was reported in 13 to 39% vs 17 to 55% of cases while early deaths occurred in 7 to 33% vs 9 to 37%. [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] As for the present study, mucositis and diarrhoea were reported to occur less frequently during ID-AraC while central nervous system toxicity was limited to patients receiving HD-AraC. The hematologic toxicities encountered during the abovementioned trials did not depend on the dose level of AraC (neutropenia 25 to 28 days vs 19 to 33 days).
In summary, the results of the present study strongly suggest a higher antileukemic efficacy of HD-AraC as compared with ID-AraC particularly in the high-risk group of patients with refractory AML or with a short remission duration. These data also indicate that the efficacy of AraC may be increased by doses beyond 1.0 gm 2 and thus suggest additional mechanisms of drug activity besides the formation of AraC triphosphate. To take full advantage of the potential benefits of Hd-AraC an improvement of supportive care is warranted to prevent the counteracting risk of exaggerated infectious deaths. This approach may be achieved by hematopoietic growth factors and new antimicrobial strategies for the effective prophylaxis and early intervention of infections.
